title: Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores.
abstract: The discovery of (+/-)-(2S,3R,4R)-2-(trifluoroacetamido)methyl-3-amino-1-(N'-ethyl-N'-isopropylcarbamyl)pyrrolidine-4-carboxylic acid (A-192558, 20e) as a potent inhibitor of influenza neuraminidase (NA) is described. Efficient syntheses of two core structures, cis-3-(allyloxycarbonyl)amino-1-(9'-fluorenylmethoxycarbonyl)pyrrolidine-4-carboxylic acid (7) and tert-butyl (+/-)-(2S,3R,4R)-2-aminomethyl-3-bis(tert-butyloxycarbonyl)amino-1-(N'-ethyl-N'-isopropylcarbamyl)pyrrolidine-4-carboxylate (18b), were developed. Starting with these core structures and using available structural information of the NA active site as the guide, analogues were synthesized in both the tri- and tetrasubstituted pyrrolidine series by means of high-throughput parallel synthesis in solid or solution phase for expeditious SAR. These studies accelerated the identification of (+/-)-(2S,3R,4R)-2-(trifluoroacetamido)methyl-3-amino-1-(N-ethyl-N-isopropylcarbamyl)pyrrolidine-4-carboxylate (20e, A-192558) as the most potent NA inhibitor in this series (IC50 = 0.2 microM against NA A and 8 microM against NA B). The X-ray crystallographic structure of A-192558 bound to NA revealed the predicted interaction of the carboxylic group with the positively charged pocket (Arg118, Arg292, Arg371) and interaction of the trifluoroacetamino residue with the hydrophobic pocket (Ile222, Trp178) of the enzyme active site. Surprisingly, the ethyl and isopropyl groups of the urea functionality induced a conformational change of Glu276, turning the Glu276/Glu277 hydrophilic pocket, which normally accommodates the triglycerol side chain of substrate sialic acid, into an induced hydrophobic pocket.
authors: Pharmaceutical Product Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA. gary.t.wang@abbott.com
authors: G T
authors: GT
authors: Wang
authors: Y
authors: Y
authors: Chen
authors: S
authors: S
authors: Wang
authors: R
authors: R
authors: Gentles
authors: T
authors: T
authors: Sowin
authors: W
authors: W
authors: Kati
authors: S
authors: S
authors: Muchmore
authors: V
authors: V
authors: Giranda
authors: K
authors: K
authors: Stewart
authors: H
authors: H
authors: Sham
authors: D
authors: D
authors: Kempf
authors: W G
authors: WG
authors: Laver
mesh_terms: D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000737:chemistry; D018360:Crystallography, X-Ray; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry; D008958:Models, Molecular; D015394:Molecular Structure; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D009975:Orthomyxoviridae / Q000201:enzymology*; D011759:Pyrrolidines / Q000138:chemical synthesis* / Q000737:chemistry
chemical_list: C424911:A 192558; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D011759:Pyrrolidines; D009439:Neuraminidase